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Endothelin-1 receptor blockade prevents renal injury in experi-
mental hypercholesterolemia.
Background. The potent vasoconstrictor endothelin-1 is in-
volved in regulation of renal function, and is up-regulated in
hypercholesterolemia (HC), a risk factor for renal disease that
increases oxidative stress and impairs renal hemodynamic re-
sponses. However, the involvement of endothelin (ET) in this
disease process is yet unknown.
Methods. Regional renal hemodynamics and function in
vivo were quantified in pigs at baseline and during infusion of
acetylcholine using electron beam computed tomography after
a 12-week normal diet (N  6), HC diet (N  6), and HC
diet orally supplemented (4 mg/kg/day) with the selective ET
receptor-A (ET-A) blocker ABT-627 (HCET-A, N  6).
Plasma levels of 8-epi-PGF2--isoprostanes, markers of oxida-
tive stress, were measured using enzyme immunoassay, and
renal tissue was studied ex vivo using Western blotting, electro-
phoretic mobility shift assay, and immunohistochemistry.
Results. Total and low-density lipoprotein (LDL) choles-
terol were similarly increased, but isoprostanes were decreased
in HCET-A compared to HC alone. Basal renal perfusion
was similar among the groups, while glomerular filtration rate
(GFR) increased in HCET-A compared to HC. Stimulated
perfusion and GFR were blunted in HC, but normalized in
HCET-A. Moreover, ET blockade increased expression of
endothelial nitric oxide synthase, and decreased endothelial
expression of the oxidized-LDL receptor LOX-1, as well as
tubular immunoreactivity of inducible nitric oxide synthase,
nitrotyrosine, nuclear factor-B, transforming growth factor-,
and tubulointerstitial and perivascular trichrome staining.
Conclusion. ET-A blockade improves renal hemodynamic
and function in HC, and decreases oxidative stress, and renal
vascular and tubulointerstitial inflammation and fibrosis. These
findings support a role for the endogenous ET system in renal
injury in HC and atherosclerosis.
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The predominant isoform of the endogenous endo-
thelin system is endothelin (ET)-1, a potent and long-
lasting renal vasoconstrictor involved in the regulation
of vascular tone [1] with pronounced atherogenic and
mitogenic properties [2], whose actions are mediated by
the specific ET-A and ET-B receptors [3]. ET-1 produc-
tion is increased in systemic cardiovascular disease like
early atherosclerosis [2, 3] and hypercholesterolemia (HC)
[4, 5], which can disrupt the delicate balance between
endothelium-derived vasoactive factors. Indeed, coro-
nary [4] and peripheral [6] endothelial function was re-
stored in experimental HC during ET blockade, support-
ing the role of ET-1 as an early contributor to endothelial
dysfunction in HC [5].
We have previously shown [7–10] that diet-induced
HC in the swine was associated with impaired renal per-
fusion and tubular responses to challenge, accompanied
by increased generation of reactive oxygen species (ROS),
or increased oxidative stress. HC and ROS have been
implicated in the pathogenesis of renal injury by direct
cellular toxicity, partly through liberation of vasocon-
strictor-bioactive lipids and inactivation of nitric oxide
(NO) [11]. Furthermore, ROS increase synthesis of ET-1
[12] and act as second messengers of this peptide [13].
ET-1 may, in turn, increase superoxide anion (O2) and
peroxynitrite production [14, 15], and promote uptake of
oxidized low-density lipoprotein (ox-LDL) by its specific
receptor LOX-1 [16], thereby contributing to develop-
ment and progression of endothelial dysfunction and
atherosclerosis. Indeed, ET could conceivably mediate
some of the renal effects of HC. However, the possible
role of ET-1 in renal functional impairment and the
potential beneficial effects of endothelin receptor block-
ade on the kidney in early HC remain elusive.
Electron beam computed tomography (EBCT) pro-
vides accurate and noninvasive measurements of single-
kidney regional hemodynamics and function in vivo,
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which agree well with conventional measures [17]. There-
fore, EBCT enables quantification of subtle alterations
in the hemodynamics and function of the intact kidney
[8, 10, 17, 18]. This scanner affords a unique opportunity
to study the intrarenal effects resulting from endogenous
endothelin blockade in HC. Therefore, the present study
was designed to examine whether blockade of the endog-
enous endothelin system in HC pigs improved renal he-
modynamics and functional responses, as well as renal
tissue injury.
METHODS
Procedures were approved by the Institutional Animal
Care and Use Committee. Eighteen domestic crossbred
pigs of similar body weight (50 to 60 kg each) were studied
after 12 weeks of normal (N  6), 2% HC (N  6) [4,
8, 10], or HC diet orally supplemented with the selective
endothelin receptor-A blocker ABT-627 (HCET-A,
N  6) on a weight-adjusted scale to maintain a dose of
4 mg/kg per day [4]. ABT-627 is an orally active, nonpep-
tide selective ET-A receptor antagonist that has been
fully characterized and has a binding Ki for the ET-A
receptors approximately 2000-fold greater than for the
ET-B receptors (0.035 nmol/L and 69.5 nmol/L, respec-
tively) [19, 20]. The dosage of ABT-627 was based on
drug level determinations in prior in vivo studies that
demonstrated an attenuated blood pressure response to
ET-1 infusion [4, 21, 22].
Following completion of 12 weeks of diet, in vivo
EBCT studies were performed for assessment of renal
regional perfusion, renal blood flow (RBF), glomerular
filtration rate (GFR), and tubular function. On the day
of the study, each animal was anesthetized with 0.5 g
of intramuscular ketamine and xylazine, intubated, and
mechanically ventilated with room air. Anesthesia was
maintained with a mixture of ketamine (0.2 mg/kg/min)
and xylazine (0.03 mg/kg/min) in normal saline, adminis-
tered via an ear vein cannula (0.05 mL/kg/min) as pre-
viously described [8, 9]. Catheters were placed in the aorta
(a few centimeters above the level of the renal arteries)
and the superior vena cava. Forty consecutive EBCT
scans (over 3 minutes) were subsequently performed
at variable time intervals after a central venous bolus
injection (0.5 mL/kg) of the nonionic, low-osmolar con-
trast medium iopamidol (Isovue-370; Squibb Diagnos-
tics, Princeton, NJ, USA). The studies were performed at
baseline, and then repeated during intra-aortic infusion
of the endothelium-dependent vasodilator acetylcholine
(Ach, 4.5 g/kg/min). The 8-epi-PGF2- isoprostanes,
considered the most ubiquitous and reliable oxidative
stress markers [18, 23, 24], were measured in systemic
venous plasma using an enzyme immunoassay (EIA)
(Cayman, Ann Arbor, MI, USA) [18, 23, 24]. This assay
has high accuracy (correlation coefficient of 0.99 on a
standard curve), specificity of 98%, and interassay vari-
ability 10% [23, 25].
Pigs were then euthanized with intravenous sodium
pentobarbital (100 mg/kg) and in vitro studies per-
formed. Renal morphology was evaluated in 5 m cross-
sections stained with hematoxylin and eosin (H&E) and
trichrome [8]. Protein expression of transforming growth
factor (TGF)- and the specific oxidized-LDL receptor
LOX-1 was measured using Western blot and immuno-
histochemistry. Expression of the pro-inflammatory nu-
clear factor kappa B (NFB) was evaluated using immu-
nohistochemistry, and confirmed using electrophoretic
mobility shift assay (EMSA). In addition, using either
frozen or deparaffinized 5 m-thick cross-sections, as
detailed previously [8], to evaluate immunoreactivity for
endothelial- (eNOS) and inducible- (iNOS) nitric oxide
synthase, and nitrotyrosine (footprint for peroxynitrite
formation).
Protein extraction and Western blotting
Frozen renal tissue was pulverized and homogenized
at 4	C in chilled protein extraction buffer. The homoge-
nate was incubated in buffer for 1 hour at 4	C, and the
homogenized lysates then centrifuged for 15 minutes at
14,000 rpm. The supernatant was removed and the pro-
tein concentration determined by a Coomassie assay.
The lysate was diluted 1:4 in 1
 Page Sample Buffer,
sonicated, and heated at 95	C to denature the proteins.
The lysate was then loaded onto a gel, and subsequently
run as per standard Western blotting protocols using
specific antibodies against TGF- and LOX-1 (1:200
each; Santa Cruz Biotechnology, CA, USA). The mem-
brane was finally exposed to x-ray film (Kodak, Roches-
ter, NY, USA), which was subsequently developed [26].
Electrophoretic mobility shift assay (EMSA)
EMSA was performed according to established proto-
cols [27, 28]. Renal tissue was homogenized in a buffer
[N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
(HEPES) 10 mmol/L (pH 7.8), KCl 15 mmol/L, MgCl2
2 mmol/L, ethylenediaminetetraacetic acid (EDTA) 0.1
mmol/L, dithioreitol (DTT) 1 mmol/L, and phenylmeth-
ylsulfonyl fluoride (PMSF) 1 mmol/L] and centrifuged
(4000 g for 10 min). The pellet was resuspended in a
homogenization buffer with KCl concentration of 0.39
mol/L, at 4	C for 1 hour. The probe was subsequently
ultracentrifuged at 100,000 g for 30 minutes and the
supernatant dialyzed overnight in a buffer [HEPES 50
mmol/L (p.H. 7.8), KCl 50 mmol/L, EDTA 0.1 mmol/L,
DTT 1 mmol/L, PMSF 1 mmol/L, and 10% glycerol].
The dialyzed supernatant was analyzed for protein con-
centration by a Coomassie assay and stored at –80	C for
subsequent gel shift assays. These were performed as
two competition assays [unlabeled nonspecific (SP1) and
specific (NFB) consensus oligos] with a commercially
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available kit (Promega, Madison, WI, USA) and nuclear
extracts from HeLa cells (Promega) as positive sample
controls. Probes of tissue samples and nuclear extracts
were loaded to 5% TBE gels and run for 45 minutes at
250 V at 4	C. Radioactivity in each probe was adjusted
to 250,000 cpm and protein content to 5 g. Following
electrophoresis, gels were placed on filter paper, dried
on a gel dryer, and exposed to an x-ray film (Kodak)
with an intensifying screen for 1 hour at –80	C. X-ray
films were developed using an automated film-devel-
oping machine.
Immunostaining for eNOS, nitrotyrosine, and LOX-1
was performed in frozen 5 m-thick cross-sections, as
described previously [8]. Monoclonal antibodies for eNOS
(1:500; Transduction-Laboratories, Lexington, KY, USA),
nitrotyrosine residues (1:20; Cayman) [8], and for LOX-1
(1:280) served as primary antibodies. The Vectastain-
Elite ABC Kit (Vector Laboratories, Burlingame, CA,
USA) was used following vendor’s instructions.
Immunostaining for iNOS, NFB, and TGF-was per-
formed on deparaffinized renal 5 m-thick cross-sec-
tions. Polyclonal iNOS (1:500; Affinity Bioreagents,
Golden, CO, USA), and TGF- (1:10; Santa Cruz Bio-
technology, Inc.), and monoclonal NFB (1:50; Santa
Cruz Biotechnology Inc.) primary antibodies were uti-
lized. The secondary antibody, immunoglobulin (Ig) G
(Envision Plus; Dako, Carpinteria, CA, USA), was fol-
lowed by staining with the Vector NovaRED substrate
kit (Vector Laboratories), and slides were counter-
stained with hematoxylin [8].
Data analysis
Renal regional perfusion (mL/minute/g), intratubular
fluid concentration (ITC), which reflects the concentra-
tion of contrast media and serves as an index of tubular
fluid-reabsorption, single-kidney GFR, and RBF were
calculated from EBCT time-density curves obtained
from renal cortex and medulla using previously validated
methods [8, 10, 17, 18]. Representative histologic mid-
hilar cross sections of the kidney (1 per animal) were
examined using a computer-aided image analysis pro-
gram (Meta Imaging Series 4.6, MetaMorph, Universal
Imaging Corporation, Downingtown, PA, USA). In each
representative slide, immunostaining or trichrome stain-
ing was semi-automatically quantified in 15 to 20 fields
by the computer program, and expressed as percentage
of staining of total surface area, and the results from
all fields averaged [8]. The H&E slides were analyzed
visually and qualitatively for the presence of glomerulo-
sclerosis. Renal arteriolar media-to-lumen ratio was as-
sessed following standard techniques [8, 29].
Statistical analysis
Data are mean SEM, and in vivo data were compiled
from both kidneys. Comparisons among the groups were
performed using analysis of variance (ANOVA) with
the Bonferroni correction and unpaired Student t test,
and within groups using paired Student t test. Statistical
significance was accepted for P  0.05.
RESULTS
Serum cholesterol levels were similarly elevated in
HC and HCET-A (Table 1). Total isoprostanes were
higher in HC compared to normal, but not different
from normal in HCET-A (Table 1). There were no
significant differences among the groups in mean arterial
pressure (Table 1).
Renal hemodynamics and function
Basal RBF, cortical and medullary perfusions were
similar among the groups, while in HCET-A GFR was
increased compared to HC (Table 1). Basal ITC was
similar in normal and HC, whereas in HCET-A proxi-
mal tubular ITC was lower compared to HC, and tended
to be lower compared to normal, as well (Table 1).
In normal animals, Ach increased RBF, GFR, and
cortical and medullary perfusions (Fig. 1). In HC, GFR
significantly increased, but the increase was attenuated
compared to normal, and RBF and regional perfusion re-
mained unchanged. On the other hand, in HCET-A pigs
Ach increased RBF, GFR, cortical and medullary perfu-
sion (Fig. 1 A to D). Renal tubular response was also
different among the groups. In normal animals, Ach tended
to decrease ITC in the distal and collecting tubules (P 
0.07, data not shown), while in the proximal tubule and
the loop of Henle, ITC remained unchanged. In HC, Ach
induced a significant decrease in ITC in the proximal and
distal tubules (P  0.03 for both), while in HCET-A,
ITC significantly decreased in loop of Henle, distal tu-
bules, and collecting duct (P  0.02 for all).
Renal tissue
H&E slides did not reveal overt glomerular or vascular
sclerosis in HC. However, the media-to-lumen ratio in
HC was significantly greater than normal, and trichrome
staining showed increased perivascular and tubulointer-
stitial fibrosis (Table 2, Fig. 2A), which were associated
with significantly increased tubular and glomerular
TGF- expression. These findings were significantly at-
tenuated in HCET-A (Table 2, Fig. 3A).
Immunoreactivity of eNOS in renal arteriolar endothe-
lial cells was attenuated in HC compared to normal, but
normalized in HCET-A (Fig. 2B), suggesting increased
potential for NO production. Proximal and distal tubular
immunoreactivity for iNOS, and global tubular and glo-
merular expression of nitrotyrosine (the marker for per-
oxynitrite formation in vivo), were higher in HC com-
pared with normal, suggesting pro-inflammatory changes
and increased generation of ROS, but were largely de-
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Table 1. Systemic and renal characteristics in normal, hypercholesterolemic (HC), and HCET-A pigs
Normal HC HCET-A
(N  6) (N  6) (N  6)
Total cholesterol mmol/L 1.670.16 10.60.9a 10.71.1a
Low-density lipoprotein mmol/L 0.580.12 7.60.8a 7.80.9a
Mean arterial pressure mm Hg 1125.7 118.24.3 1165.5
Isoprostanes pg/mL 116.415.5 23829.7a 154.414.4b
Renal blood flow mL/min 542.826.1 545.948.6 518.237.6
Glomerular filtration rate mL/min 75.43.1 63.14.7 84.56.6b
Perfusion mL/min/cc
Cortex 4.30.3 4.40.4 4.00.3
Medulla 2.80.3 3.10.5 3.20.4
Intratubular contrast concentration arbitrary units
Proximal tubule 3.70.2 4.50.2 3.10.3b,c
Henle’s loop 8.71.2 7.10.4 9.11.3
Distal tubule 7.00.9 7.00.4 7.10.6
Collecting duct 11.91.4 12.01.8 9.11.7
ET-A is endothelin receptor A. Data are mean  SEM.
a P  0.05 vs. normal
b P  0.05 vs. HC
c P  0.1 vs. normal
Fig. 1. (A ) Renal blood flow, (B ) glomerular filtration rate, (C ) corti-
cal, and (D ) medullary perfusion under basal conditions and in response
to acetylcholine in normal, hypercholesterolemic (HC), and HCET-A
groups. *P  0.05 vs. baseline; †P  0.05 vs. HC; #P  0.05 vs. normal.
creased in HCET-A (Fig. 2 C to D). A similar pattern
was also observed in the expression of NFB in proximal
tubules (Table 2, Fig. 4), which was subsequently verified
by EMSA (Fig. 4). Moreover, expression of the LOX-1
receptor was increased in HC renal endothelial cells, and
Table 2. Tissue staining (% of renal area), in normal,
hypercholesterolemic (HC), and HCET-A kidneys
Normal HC HCET-A
(N  6) (N  6) (N  6)
Trichrome 3.20.06 5.80.6a 3.80.2a,b
Media-lumen ratio 0.20.01 0.270.02a 0.170.01a,b
Transforming growth factor- 1.00.06 2.30.2a 1.20.07a,b
Endothelial NOS 7.60.3 4.90.4a 8.10.3b
Inducible NOS 3.40.4 8.90.6a 5.10.3a,b
Nitrotyrosine 7.40.3 8.90.1a 6.50.3a,b
Nuclear factor-B 0.30.02 1.90.3a 0.70.04a,b
LOX-1 2.20.2 3.20.2a 2.70.2c
Abbreviations are: ET-A, endothelin receptor A; NOS, nitric oxide synthase;
LOX, lectin-like oxidized LDL receptor. Data are meanSEM.
a P  0.05 vs. normal
b P  0.05 vs. HC
c P  0.06 vs. normal and HC
decreased in HCET-A (Table 2, Fig. 3B), suggesting
that ET-A blockade decreased the potential for ox-LDL
uptake in renal tissue.
DISCUSSION
This study demonstrates that endothelin A-receptor
blockade in HC elevates GFR and improves renal hemo-
dynamic and functional responses to an endothelium-
dependent vasodilator, implying involvement of the en-
dothelin system in the blunted renal responses observed
in HC. These may be achieved by correction of the vaso-
constrictor/vasodilator imbalance, which characterizes HC
and atherosclerosis. Furthermore, these beneficial effects
were accompanied by decreased oxidative stress, increased
eNOS, and decreased endothelial LOX-1 expression, de-
creased tubular iNOS, nitrotyrosine, NFB, and TGF-
immunoreactivity, and decreased perivascular and tubu-
lointerstitial trichrome staining. Thus, blockade of the
endogenous endothelin system in HC decreased vascu-
Fig. 2. Representative renal staining for (A ) trichrome, (B ) eNOS, (C ) iNOS, and (D ) nitrotyrosine in normal, hypercholesterolemic (HC), and
HC  ET-A groups. These show decreased perivascular and tubulointerstitial fibrosis and suggest increased availability of NO and decreased
inflammation in HCET-A. (Magnification, 
20).
Fig. 4. Representative renal immunohisto-
chemistry and electrophoretic mobility shift
assay (EMSA) that shows increased activation
of NFB in hypercholesterolemic (HC) pigs,
which was substantially attenuated in HC 
ET-A. NSC, nonspecific competitor; SC, spe-
cific competitor. Magnification, 
20.
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Fig. 3. Representative renal immunoblots and immunohistochemistry
demonstrating protein expression of (A ) the profibrotic transforming
growth factor (TGF)- and (B ) the ox-LDL receptor LOX-1 in normal,
hypercholesterolemic (HC), and HCET-A groups. *P  0.05 vs. nor-
mal; †P  0.05 vs. HC; #P  0.06 vs. normal. Magnification, 
20.
lar, glomerular, and tubulointerstitial renal inflamma-
tion and fibrosis. This study supports a role for the endog-
enous endothelin system in the mechanism of renal injury
in early atherosclerosis.
Experimental evidence suggests that lipid abnormali-
ties are associated with a decline in renal function and
participate in the progression of renal disease [30]. Accu-
mulating evidence has shown increased activity of the
endogenous ET system in both human and experimental
HC and atherosclerosis [5, 31, 32]. ET-1 is a potent vaso-
constrictor, which exerts its biological effect through
activation of specific ET-A and -B receptors [3]. ET-A
receptors mediate vasoconstriction and cell prolifera-
tion, whereas ET-B receptors are involved in ET-1 clear-
ance, inhibition of endothelial apoptosis, release of NO
and prostacyclin, inhibition of endothelin converting-
enzymes expression [32, 33], and coronary vasoconstric-
tion [34]. Recent studies showed favorable vascular ef-
fect of selective ET-A receptor antagonists, both in vivo
and in vitro, in experimental models of HC and athero-
sclerosis [4, 22], suggesting that activation of the local
ET system contributes to endothelial dysfunction and
vascular remodeling, mainly through ET-A receptors.
Notably, the renal microcirculation is particularly sus-
ceptible to ET-1, and its ET-A receptor induces NFB
expression and inflammation [35], likely mediates some
of the vascular effects of angiotensin II, and regulates re-
nal vascular resistance [1, 36, 37]. On the other hand, the
renal ET-B receptor participates in regulation of fluid
excretion in the distal nephron [38] and inhibits sodium
reabsorption in a NO-dependent fashion [39]. Indeed, pre-
vious studies have shown that selective chronic ET-A
blockade decreases renal injury and fibrosis [40], and in
ischemic acute renal failure provides greater long-term
functional and morphologic benefits than blockade of both
ET-A and ET-B [39, 41]. However, the potential role of
endothelin in instigation of renal injury in HC, and the
potential benefits of ET-A blockade on renal hemody-
namics and function, has not been tested.
Our study showed that blockade of the ET-A receptor
led to a significant increase in basal GFR in HCET-A
compared to HC. This effect may be due to reduction
in afferent vasoconstriction, or reduced constriction of
mesangial cells and a consequent increase in ultrafiltra-
tion coefficient [42]. Furthermore, Ach-stimulated RBF,
GFR, and renal-regional perfusion were largely restored.
This improvement in renal function may also result from
increased bioavailability of endogenous NO [43], conse-
quent to the augmented expression of eNOS and/or de-
crease in oxidative stress-mediated degradation of NO in
HCET-A. Recent studies have shown that ET directly
stimulates O2 production [15]. O2 may act as an intracel-
lular signal linked to growth related responses, and also
avidly interacts with NO [44], leading to vasoconstriction
and formation of peroxynitrite, which may further con-
tribute to cellular injury [45]. In support of this notion,
plasma levels of isoprostanes (in vivo markers of oxi-
dative stress) [24], as well as peroxynitrite formation
(reflecting the presence of O2 were decreased in the
HCET-A group, suggesting that ET-A blockade atten-
uates both systemic and tissue oxidative stress in HC.
Furthermore, ET-A blockade may restore the vasocon-
striction/vasodilation balance, which is disrupted in HC
and impairs the regulation of vascular tone [46].
In addition, we have previously shown that HC was
associated with decreased proximal reabsorption in re-
sponse to Ach, possibly due to tubular inflammatory
changes and iNOS-derived NO [8–10]. In the current
study, the decrease in basal proximal fluid reabsorption
observed in HCET-A may have been a result of blocking
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the effects of AII and/or ET in the proximal tubule [47],
similar to our observation using an angiotensin II type 1
(AT1) receptor blocker [7]. However, the proximal tubu-
lar response to Ach in HCET-A was similar to that
observed in normal animals, conceivably due to attenu-
ated proximal tubular expression of iNOS. On the other
hand, similar to HC, the decrease in fluid reabsorption
in the distal nephron in response to Ach remained en-
hanced in HCET-A, and might have resulted from
increased activation of the ET-B receptor in the collect-
ing duct [48] in the face of ET-A blockade.
In addition to its functional effects, ET-1 is also in-
volved in cell proliferation, inflammation [35], and growth
factor expression that may lead to renal fibrosis [49]. We
observed in HC increased expression of iNOS (in the
proximal and distal tubules) and NFB (in the glomeruli
and proximal tubule), which are involved in renal in-
flammation [8]. Furthermore, this was accompanied by
increased expression in renal arterioles of LOX-1, the
specific receptor that facilitates the uptake of the cyto-
toxic ox-LDL, which may also contribute to renal injury.
Indeed, a previous study has shown that ET-1 increases
the expression of LOX-1 in human endothelial cells in
vitro [16]. Our study demonstrates, for the first time,
that ET-A blockade in diet-induced HC attenuates not
only renal iNOS and NFB, but also LOX-1 expression
in vivo, which might serve as a mechanism for renal
protection. Moreover, this was associated with markedly
decreased tubular and glomerular expression of TGF-
and attenuated perivascular and tubulointerstitial fibro-
sis, suggesting an overall decrease in renal injury in
HCET-A.
CONCLUSION
The current study demonstrates, for the first time,
that ET-A blockade augments GFR and preserves renal
hemodynamic responses in the intact kidney of pigs with
diet-induced HC associated with decreased oxidative
stress, inflammation, and fibrosis in renal tissue. Further
studies will be needed to evaluate the potential of ET-
blockade to reverse pre-established renal injury in longer
duration of HC and the effect of ET-A blockade on the
normal kidney. Our findings suggest involvement of the
endothelin system in the mechanism of renal injury in
HC and atherosclerosis and support a role for these
agents in renal protection.
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